Genetic Technologies gets tough
Monday, 14 July, 2008
Genetic Technologies (ASX: GTG) will enforce its exclusive rights to perform diagnostic testing of the BRCA1 and BRCA2 breast cancer genes in Australia and New Zealand.
The company has been paying ongoing licence fees to Myriad Genetics for exclusive rights to perform diagnostic testing but has been allowing other service providers to perform BRCA testing for the last five years.
Genetic Technologies said in a statement it was now enforcing those exclusive rights, preventing several laboratories throughout the country from performing the test.
It said it had invested several million dollars in a high-throughput molecular diagnostic laboratory and had reduced turnaround time to four weeks.
Alloy implants that naturally dissolve after healing
Australian researchers have been developing biodegradable magnesium-based alloys that more...
Partnership eyes up gene-editing approaches to vision loss
A partnership will build on Australian ophthalmic research into mechanisms that damage nerve...
Irregular blood pressure patterns and dementia-associated brain changes
Hypertension has long been recognised as a risk factor for cognitive decline, yet the impact of...
